Vergleich

Myelin Basic Protein (MBP) (68-82), guinea pig

ArtNr CS-0025318-10mg
Hersteller ChemScene
Menge 10mg
Kategorie
Typ Molecules
Specific against other
ECLASS 10.1 32169090
ECLASS 11.0 32169090
UNSPSC 12000000
Similar products 98474-59-0
Lieferbar
CAS
98474-59-0
Purity
>98%
Formula
C71H113N23O28
MWt
1736.79
Solubility
H2O
Clinical Information
No Development Reported
Pathway
Others
Target
Others
Biological Activity
Myelin Basic Protein (MBP) (68-82), guinea pig is a fragment of myelin basic protein (MBP). In Vitro: Multiple sclerosis is the most common autoimmune disorder affecting the central nervous system. In this study, whole blood samples are analyzed for activation capacity and the activatability of CD4+ and CD8+ T-lymphocytes by human total myelin basic protein (MBP), human MBP 104-118 fragment, and guinea pig MBP (68-82) fragment. A significant increase in the number of activated T-lymphocytes was observed in the whole blood. For all three tested MBPs, this increase in activated CD4+ and CD8+ T-lymphocytes is statistically significant (p<0.01). However, this increase in activated T-cells is most prominent following incubation with human total MBP, followed by human 104-118 fragment; the smallest increase is observed following incubation with guinea pig MBP (68-82) fragment (human total MBP>huMBP-104-118>guinea pig MBP (68-82))[1]. In Vivo: Whether pretreatment with bee venom acupuncture (BVA) from the same day of MBP (68-82) immunization can affect the induction and progression of experimental autoimmune encephalomyelitis (EAE) and weight loss is examined. At 5-9 days after immunization, rats in the myelin basic protein (MBP) group start displaying partial loss of tail tonus (clinical signs, 0.5) in a freely moving environment. At 10-16 days after immunization, most of the rats in the MBP group display more severe symptoms of neurological deficit including paraparesis of the hindlimb, paraplegia, tetraparesis, and tetraplegia. In contrast, rats in the MBP?+?BVA group display relatively slight neurological deficits in a dose-dependent manner at 11-15 days after immunization, compared to the rats in the MBP group. The onset of symptoms is slightly delayed (BVA 0.8 mg/kg, 6.4+/-0.6 days) and the maximal clinical score is markedly decreased (BVA 0.25 mg/kg, 3.7+/-0.2; BVA 0.8 mg/kg, 2.8+/-0.3), compared to that in the MBP group. At this time, the mean body weight of rats in the MBP group is decreased as compared to that of rats in the normal group, but it is significantly increased in rats of the MBP?+?BVA group as compared to rats in the MBP group[2].

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Menge: 10mg
Lieferbar: In stock
lieferbar

Vergleichen

Auf den Wunschzettel

Angebot anfordern

Lieferzeit anfragen

Technische Frage stellen

Bulk-Anfrage stellen

Fragen zum Produkt?
 
Schließen